Wide Ranks

BPMC

Blueprint Medicines Corporation

95.10

Top Statistics
Market Cap 6 B Forward PE -125.08 Revenue Growth 126.60 %
Current Ratio 3.32 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -29.48 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -23.04 Enterprise / Revenue 13.90 Price To Sales Trailing12 Months 13.91
Profitability
Profit Margins -29.48 % Operating Margins -38.21 %
Balance Sheet
Total Cash 734 M Total Cash Per Share 11.56 Total Debt 732 M
Total Debt To Equity 233.98 Current Ratio 3.32 Book Value Per Share 4.93
All Measures
Short Ratio 559.00 % Message Board Id finmb_129802746 Shares Short Prior Month 3 M
Return On Equity -0.4965 City Cambridge Uuid ff898492-23d6-3cda-8698-a93cfd1e435b
Previous Close 94.63 First Trade Date Epoch Utc 1 B Book Value 4.93
Beta 0.5900 Total Debt 732 M Volume 813528
Price To Book 19.27 Fifty Two Week Low 68.28 Total Cash Per Share 11.56
Total Revenue 434 M Shares Short Previous Month Date 1 B Target Median Price 130.00
Max Age 86400 Recommendation Mean 1.95 Sand P52 Week Change 0.3133
Operating Margins -38.21 % Target Mean Price 125.58 Net Income To Common -128049000
Short Percent Of Float 0.0694 Implied Shares Outstanding 63 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 695350 Average Volume10days 695350
Total Cash 734 M Next Fiscal Year End 1 B Revenue Per Share 6.99
Held Percent Insiders 0.0090 Ebitda Margins -60.34 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 94.63
Target Low Price 81.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 90.79
Open 95.25 Free Cashflow -101520128 State MA
Dividend Yield 0.00 % Return On Assets -0.1497 Time Zone Short Name EST
Trailing Eps -2.09 Day Low 92.53 Address1 45 Sidney Street
Shares Outstanding 63 M Price Hint 2 Target High Price 167.00
Website https://www.blueprintmedicines.com 52 Week Change 0.3656 Average Volume 648782
Forward Eps -0.9400 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 310.50 % Is_sp_500 False Regular Market Day High 95.54
Profit Margins -29.48 % Debt To Equity 233.98 Fifty Two Week High 121.90
Day High 95.54 Shares Short 3 M Regular Market Open 95.25
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 13.90
Revenue Growth 126.60 % Shares Percent Shares Out 0.0616 Operating Cashflow -242150000
Currency USD Time Zone Full Name America/New_York Market Cap 6 B
Is_nasdaq_100 False Zip 02139 Quote Type EQUITY
Industry Biotechnology Long Name Blueprint Medicines Corporation Regular Market Day Low 92.53
Held Percent Institutions 1.04 Current Price 95.10 Enterprise To Ebitda -23.04
Financial Currency USD Current Ratio 3.32 Gross Margins 97.02 %
Industry Disp Biotechnology Number Of Analyst Opinions 19 Country United States
Float Shares 62 M Two Hundred Day Average 96.39 Enterprise Value 6 B
Price To Sales Trailing12 Months 13.91 Forward PE -125.08 Regular Market Volume 813528
Ebitda -262128992 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.

The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.

In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers.

It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co.

, Ltd.

The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011.

Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.